On the morning of the 29th, hair loss treatment-related stocks are collectively showing strength in the domestic stock market, attracting investors' attention. An upward trend has emerged as buying interest spreads across the pharmaceutical and biotech sectors amid growing expectations for the expansion of the hair loss treatment market.

In the market that day, Daewoong Pharmaceutical led the rally with a surge of more than 10%. Boryung, Hyundai Pharm, JW Pharmaceutical, and Myungmoon Pharmaceutical also extended their gains, helping to improve investment sentiment in the pharmaceutical sector, while Chaperone also drew attention by recording a double-digit increase.

The hair loss treatment market is regarded as a key growth area in the global pharmaceutical industry, as demand expands not only with the aging population but also among younger age groups. In particular, beyond existing oral medications and topical treatments, active development of various next-generation treatment technologies is underway, including stem cell therapy, gene therapy, and RNA-based new drugs.

Domestic pharmaceutical companies are also accelerating research and development related to hair loss treatments and the expansion of their existing pharmaceutical businesses. Accordingly, the hair loss-related theme is evaluated as a sector that continues to attract market attention depending on new drug development news, clinical trial progress, and the possibility of technology transfers.

In addition to major stocks of the day, hair loss, skin, and biotech-related stocks such as Bioneer, TS Trillion, Shin Shin Pharmaceutical, Withers Pharmaceutical, Antrogen, and Kangstem Biotech also rose in tandem, spreading warmth across the sector.

The prevailing analysis in the securities market is that as investment sentiment in the biotech and pharmaceutical sectors has recently improved, the fundamental growth potential of the hair loss treatment market and expectations for new drug development are converging, rapidly increasing interest in related companies.

However, there is also a cautionary investment opinion that hair loss treatment-related stocks may experience increased price volatility depending on future clinical trial results, product approvals, technology transfers, and commercialization progress, and therefore investors should carefully examine the business details of individual companies.

[This article was written with AI assistance. Based on publicly available data, this article was partially supported by AI in the writing process and was produced after final editing and fact-checking. This article is not intended to solicit investment, and the final judgment and responsibility for investments lie with the investor.]